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Summary
Background Lateral epicondylitis is generally treated with
corticosteroid injections or physiotherapy. Dutch clinical
guidelines recommend a wait-and-see policy. We compared
the efficacy of these approaches.
Methods Patients with lateral epicondylitis of at least 
6 weeks’ duration were recruited by family doctors. We
randomly allocated eligible patients to 6 weeks of treatment
with corticosteroid injections, physiotherapy, or a wait-and-
see policy. Outcome measures included general
improvement, severity of the main complaint, pain, elbow
disability, and patient satisfaction. Severity of elbow
complaints, grip strength, and pressure pain threshold were
assessed by a research physiotherapist who was unaware of
treatment allocation. We assessed all outcomes at 3, 6, 12,
26, and 52 weeks. The principal analysis was done on an
intention-to-treat basis.
Findings We randomly assigned 185 patients. At 6 weeks,
corticosteroid injections were significantly better than all
other therapy options for all outcome measures. Success
rates were 92% (57) compared with 47% (30) for
physiotherapy and 32% (19) for wait-and-see policy. However,
recurrence rate in the injection group was high. Long-term
differences between injections and physiotherapy were
significantly in favour of physiotherapy. Success rates at 52
weeks were 69% (43) for injections, 91% (58) for
physiotherapy, and 83% (49) for a wait-and-see policy.
Physiotherapy had better results than a wait-and-see policy,
but differences were not significant. 
Interpretation Patients should be properly informed about
the advantages and disadvantages of the treatment options
for lateral epicondylitis. The decision to treat with
physiotherapy or to adopt a wait-and-see policy might depend
on available resources, since the relative gain of
physiotherapy is small. 
Lancet 2002; 359: 657–62
Introduction
Lateral epicondylitis (tennis elbow) is a frequent
complaint in primary care, and is judged an overload
injury, affecting the common extensor muscles at the
lateral humeral epicondyle. The incidence of lateral
epicondylitis is estimated at 4–7 per 1000 patients per
year in general practice,1 and between 1% and 3% per
year of adults in the general population are affected.2–5 A
typical episode of lateral epicondylitis lasts 6–24 months
on average,6,7 but most patients recover within a year.8,9
Systematic reviews of the effectiveness of
physiotherapy, corticosteroid injections, and non-steroidal
anti-inflammatory drugs for lateral epicondylitis present
conflicting results.10,11 Labelle and colleagues11 concluded
that there is insufficient evidence for any specific
treatment. The methodological quality of research is
generally poor, and the statistical power of most
randomised controlled trials is low.10–16 Corticosteroid
injections seem safe and effective in the short-term
treatment of lateral epicondylitis.10 However, there is
insufficient evidence with respect to their long-term
effectiveness.
In view of the absence of scientific data for the
effectiveness of active interventions, and the benign
course of lateral epicondylitis, the clinical guidelines of 
the Dutch College of General Practitioners recommend 
a wait-and-see policy, including ergonomic advice and
prescription of pain medication if necessary.10 Our
aim was to compare the efficacy of a wait-and-see 




We did a randomised trial in a primary-care setting. We
considered for inclusion consecutive patients who
consulted one of 85 participating family doctors for elbow
complaints. Inclusion criteria were: pain at the lateral side
of the elbow, increasing with pressure on the lateral
epicondyle and with resisted dorsiflexion of the wrist; age
18–70 years; ability to complete questionnaires in Dutch;
and informed consent. Exclusion criteria were: treatment
of elbow complaints with physiotherapy or injections
during the preceding 6 months; bilateral elbow symptoms;
duration less than 6 weeks; presence of signs and
symptoms suggestive of another cause of elbow pain—eg,
cervical radiculopathy; congenital or acquired deformities
of the elbow; surgery of the elbow; dislocation, tendon
ruptures, or fractures in the area in the preceding 12
months; systemic musculoskeletal or neurological
disorders; and contraindications for corticosteroids. We
referred all eligible patients to one of five research centres
after a 2-week qualification period. A trained research
physiotherapist examined patients who had not shown any
signs of recovery within this period. The physiotherapist
checked all selection criteria and enrolled patients, who
gave written informed consent. The medical ethics
committee of Vrije Universiteit Medical Centre approved
our protocol. 
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Study protocol
We used a computerised random number generator to draw
up an allocation schedule. Block randomisation (permuted
blocks of three) was done after prestratification for the
duration of complaints (13 weeks or 13 weeks) and
research centre. The assignment of patients to
corticosteroid injections, physiotherapy, or a wait-and-see
policy took place after final selection by the research
physiotherapist and baseline assessment. An administrative
assistant allocated interventions via opaque sealed envelopes
marked according to the allocation schedule. The research
physiotherapist and the administrative assistant were
unaware of the block-size.
Patients allocated to the wait-and-see policy group visited
their family doctor once during the intervention period of 6
weeks. Activities that provoked pain, and practical solutions
(including ergonomic advice) were discussed with the
patient. If necessary, paracetamol (2000–4000 mg daily) or
non-steroidal anti-inflammatory drugs (NSAIDs, naproxen
1000 mg daily) were prescribed. The patient was
encouraged to await further spontaneous improvement. 
Patients assigned to corticosteroid injections were treated
by their doctors with local infiltration of 1 mL
triamcinoloneacetonide (10 mg/mL) and 1 mL lidocaine
2%. Every tender spot was identified with the needle and
injected until the patient was free of pain during resisted
dorsiflexion.17,18 The amount of fluid remaining in the
syringe was recorded. Patients were asked to avoid pain-
provoking activities, although absolute rest of the arm was
not necessary. During the 6-week intervention period, a
maximum of three injections was recommended. We gave
family doctors training in the injection technique before 
the trial. 
Physiotherapy consisted of nine treatments of pulsed
ultrasound, deep friction massage, and an exercise
programme over 6 weeks. Pulsed ultrasound (20% duty
cycle) was given with an intensity of 2 W/cm2 for
7·5 minutes per session.19 Ultrasound equipment was
checked and calibrated by the manufacturer (Enraf Nonius
BV, Delft, Netherlands) before and once during the trial.
After pain reduction, exercise treatment consisted of
progressive, slow, repetitive wrist and forearm stretching,
muscle conditioning, and occupational exercises, intensified
in four steps.20 All patients received home exercise
equipment and an instruction book. We gave all 
72 physiotherapists (31 practices) special training for
techniques required for the intervention. 
Details of the content of each treatment session and of
any adverse effects were reported on standardised forms by
family doctors and physiotherapists. We discouraged all co-
interventions during the 6-week intervention period, but
allowed prescription of pain medication if necessary.
We did outcome assessments before randomisation, once
during the intervention (3 weeks after randomisation), and
at 6, 12, 26, and 52 weeks. General improvement was
scored by the patient on a six-point Likert scale
(“completely recovered” to “much worse” compared with
baseline). For the computation of success rates, patients
who rated themselves “completely recovered” or “much
improved” were counted as successes.21 Patients also scored
the severity of their main complaint, pain during the day,
and inconvenience on an 11-point numerical rating scale
(0=no pain to 10=very severe pain).21 We assessed
functional disability with the modified pain-free function
questionnaire; a 10-item scale that consists of common
situations that might cause elbow pain22 (range 0–40 points,
40 indicating severe disability). The research
physiotherapist scored overall severity of the elbow
complaints on an 11-point scale (0=no complaints to
10=very severe complaints) after taking a standardised
history and physical examination. 
With respect to secondary outcome measures, pain-free
grip strength and maximum grip strength were measured by
the research physiotherapist with a Jamar hand
dynamometer (PGB Active Living, ‘s-Hertogenbosch,
Netherlands). The mean value (kg) of three efforts was
calculated, separated by 20 s rest intervals. Grip strength of
the affected side was presented as a ratio of the maximum
grip strength of the unaffected side.23,24 We measured
pressure pain threshold with an algometer25,26 (Pain
Diagnostics and Thermography, Great Neck, USA). The
research physiotherapist gradually applied pressure, with a
maximum of 6 kg/cm2 perpendicular to the common
extensor tendon at the elbow, until the patient indicated
that the sensation of pressure changed to pain. The mean of
three consecutive measurements separated by intervals of
20 s was taken. The pressure-pain threshold was presented
as the ratio of the pain-free pressure of the unaffected side.
Satisfaction with the received intervention was reported by
the patient on an 11-point scale (0=not satisfied at all to
10=very satisfied). 
The three research physiotherapists in the study trained
thoroughly before the trial. We did a reproducibility study
in 50 consecutive patients. Interassessor agreement was
good to excellent for gripstrength and assessment of overall
severity, and satisfactory for pressure pain threshold
(intraclass correlation coeficients 0·72–0·98).27 We
transformed all primary and secondary outcome values to
259 patients referred 
       to research centre
74 not randomised
     5 did not meet 
        inclusion criteria
   52 met exclusion 
        criteria
   17 gave no informed 
        consent 
185 randomised
59 wait-and-see 
     policy
62 corticosteroid 
     injection
64 physiotherapy
1 did not receive
   intervention 
   according
   protocol
 1 physiotherapy
59 completed trial* 60 completed trial† 64 completed trial
1 did not receive
   intervention 
   according
   protocol
 1 dose of steroids 
    too high
2 withdrew
  1 at week 12
  1 at week 26
19 did not receive
     intervention 
     according
     protocol
   15 additional 
        mobilisation
     4 other physical 
        modality
Figure 1: Trial profile
*One patient missed assessment at 3 weeks due to holiday; †one
patient missed assessment at 12 weeks due to a car accident. 
For personal use.  Only reproduce with permission from The Lancet Publishing Group.
normal distribution. We computed the differences 
(95% CI) in improvement between the groups. The
principal analysis was done on an intention-to-treat basis.
Furthermore, we did an alternative analysis, excluding all
patients who had not been treated according to protocol.
We analysed differences in improvement between the
groups for continuous outcomes by means of one-way
analysis of variance with SPSS (version 8.0). We studied the
potential effect of differences between groups on prognostic
indicators at baseline by means of MANOVA for
continuous outcomes, and logistic regression for success
rates. We used MANOVA for repeated measures to prevent
multiple testing and to ascertain differences between the
intervention with respect to the course of elbow complaints.
We judged p values less than 0·05 as significant.
We based sample-size on the ability to detect a clinically
important difference of 25% in success rate between groups
ARTICLES
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100-point scales to enable a straightforward interpretation
and comparison across outcome measures. 
Finally, the use of analgesics and all consultations with
family doctors, physiotherapists, specialists, and other
health-care providers were reported every week in a diary
kept by the patient. The diaries were collected and checked
by the administrative assistant during each subsequent visit
to the research centre. The research physiotherapist was
unaware of the allocated intervention. Before every
assessment, patients were asked by the administrative
assistant not to reveal any information about their
treatment. Immediately after every assessment, the research
physiotherapist was asked to guess the allocated treatment,
and state any reasons for their assumption. 
Statistical analysis
We calculated changes in scores over time for every patient
by subtracting the results at baseline from those at follow-
up. Although absolute scores for most outcome measures
were skewed, changes from baseline generally showed a
Wait-and-see policy (n=59) Corticosteroid Physiotherapy (n=64)
injection (n=62)
Age (median IQR) (years) 46 (42–54) 47 (41–54) 48 (41–52)
Women 31 (53%) 34 (55%) 28 (44%)
Duration of current episode of lateral epicondylitis (median IQR) (weeks) 11 (8–21) 11 (8–16) 11 (8–21)
Acute onset 13 (22%) 16 (26%) 17 (27%)
Dominant elbow affected 46 (78%) 48 (77%) 51 (80%)
Concomitant neck disorders 12 (20%) 18 (29%) 9 (14%)
Previous episodes of lateral elbow pain 18 (31%) 25 (40%) 16 (25%)
Putative cause
Overuse, usual activities 22 (37%) 16 (26%) 21 (33%)
Overuse, unusual activities 15 (25%) 15 (24%) 15 (23%)
Other (sport injury, unexpected movement) 8 (14%) 11 (18%) 12 (19%)
Unknown  14 (24%) 20 (32%) 16 (25%)
Patient’s preference for treatment
Physiotherapy 26 (44%) 22 (36%) 27 (42%)
Wait-and-see policy 1 (2%) 3 (5%) 4 (6%)
Injections 5 (9%) 6 (10%) 8 (13%)
No preference 31 (52%) 32 (52%) 27 (42%)
Use of analgesics during past week 9 (15%) 10 (16%) 8 (13%)
Primary outcome measures (median IQR)
Severity of main complaint 70 (50–80) 70 (50–80) 70 (60–80)
Pain during day 60 (30–70) 60 (40–70) 60 (40–70)
Inconvenience of elbow complaints 70 (50–80) 75 (50–90) 70 (50–90)
Severity of elbow complaints 40 (40–50) 40 (30–60) 40 (30–50)
Elbow disability 45 (35–55) 48 (38–61) 48 (38–60)
Secondary outcome measures (median IQR)
Pain-free grip strength 27 (17–48) 30 (22–50) 27 (18–43)
Maximum grip strength 83 (59–98) 72 (56–93) 84 (51–96)
Pressure-pain threshold 47 (38–65) 50 (40–61) 47 (33–62)
Data are number of patients (%) unless otherwise indicated.
Table 1: Baseline characteristics 
Wait-and-see Corticosteroid Physiotherapy
policy (n=59) injection (n=62) (n=64)
No additional treatment 45 (76%) 23 (37%) 12 (19%)
Physiotherapy 4 (7%) 13 (21%) 42 (66%)*
Corticosteroid injection 3 (5%) 21 (34%) 4 (6%)
Elbow support 2 (3%) 6 (10%) 3 (5%)
Pain medication 12 (20%) 17 (27%) 6 (9%)
Ergonomic advice by 4 (7%) 9 (15%) 2 (3%)
family doctor
Surgery of elbow 1 (2%) 2 (3%) 0
Cast 0 1 (2%) 0
Complementary medicine 0 2 (3%) 1 (2%)
Data are number of patients (%). *Additional physiotherapy was given for 
<6 weeks in 38 of 42 patients.






















Figure 2: Success rates of three treatment regimens 
For personal use.  Only reproduce with permission from The Lancet Publishing Group.
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at 6 weeks after randomisation. Assuming a success rate of
40% in the least successful group, the target sample size was
estimated at 60 patients per group (two-tailed =0·05,
=0·20).
Role of the funding source
The sponsors of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report.
Results
Between September, 1997, and October, 1998, 259
patients with lateral epicondylitis were referred to a research
centre. 185 patients met all selection criteria and were
randomly assigned. Figure 1 shows the trial profile. Three
patients enrolled should not have been, since they had loss
of strength due to stroke (injection group), had previously
had a wrist fracture (physiotherapy group), or had had a
partial paresis of the ulnaris nerve (wait-and-see group). Of
the two patients who withdrew from the study, one had fully
recovered and the other was not satisfied with treatment. 
Table 1 shows the baseline characteristics of patients.
Despite randomisation, there were slight differences
between the intervention groups with respect to
concomitant neck disorders, previous episodes of lateral
elbow pain, maximum grip strength, and presumed
Wait-and-see Corticosteroid Physiotherapy Mean differences in improvement (95% CI) p*




3 weeks 6 (14) 43 (28) 11 (18) 37 (29 to 44) 4 (–3 to 12) 32 (25 to 40) ..
6 weeks 21 (32) 46 (30) 26 (28) 24 (14 to 35) 4 (–6 to 15) 20 (10 to 31) ..
12 weeks 33 (30) 37 (30) 43 (31) 4 (–7 to 15) 10 (–1 to 21) –6 (–17 to 5) ..
26 weeks 47 (30) 36 (34) 53 (31) –11 (–22 to 1) 6 (–5 to 17) –17 (–28 to –6) ..
52 weeks 53 (28) 44 (32) 59 (25) –9 (–19 to 2) 7 (–4 to 17) –15 (–25 to –5) <0·0001
Pain during the day
3 weeks 6 (16) 36 (23) 6 (17) 30 (23 to 36) –0·1 (–7 to 7) 30 (23 to 37) ..
6 weeks 15 (23) 47 (20) 21 (23) 32 (24 to 40) 6 (–2 to 14) 26 (18 to 34) ..
12 weeks 25 (26) 33 (27) 34 (25) 8 (–1 to 18) 9 (–0·2 to 18) –0·3 (–10 to 9) ..
26 weeks 34 (26) 27 (26) 41 (27) –7 (–17 to 2) 7 (–3 to 16) –14 (–23 to 5) ..
52 weeks 39 (26) 35 (26) 46 (28) –4 (–13 to 6) 7 (–2 to 17) –11 (–20 to –2) <0·0001
Inconvenience
3 weeks 12 (17) 44 (29) 13 (20) 33 (25 to 41) 1 (–7 to 9) 31 (23 to 39) ..
6 weeks 22 (26) 60 (26) 31 (24) 37 (28 to 46) 8 (–1 to 18) 29 (20 to 38) ..
12 weeks 35 (30) 44 (33) 47 (28) 8 (–3 to 19) 12 (0·6 to 22) –3 (–14 to 8) ..
26 weeks 47 (31) 38 (36) 56 (28) –9 (–20 to 2) 9 (–3 to 20) –18 (–29 to –6) ..
52 weeks 52 (31) 49 (30) 62 (32) –4 (–15 to 8) 10 (–1 to 21) –14 (–25 to –3) <0·0001
Severity of elbow complaints
3 weeks 8 (13) 27 (20) 6 (17) 19 (12 to 25) –2 (–8 to 4) 21 (15 to 27) ..
6 weeks 13 (16) 33 (17) 13 (21) 20 (13 to 26) –0·1 (–6 to 6) 20 (14 to 26) ..
12 weeks 20 (19) 16 (28) 24 (22) –4 (–12 to 5) 5 (–4 to 13) –8 (–17 to 0·2) ..
26 weeks 27 (23) 22 (22) 32 (18) –5 (–12 to 3) 5 (–3 to 13) –10 (–17 to –2) ..
52 weeks 33 (19) 26 (22) 36 (20) –7 (–14 to 1) 4 (–3 to 11) –11 (–18 to –3) <0·0001
Elbow disability 
3 weeks 4 (12) 29 (21) 6 (17) 25 (18 to 31) 2 (–4 to 8) 22 (16 to 29) ..
6 weeks 11 (18) 38 (19) 16 (20) 27 (20 to 33) 5 (–2 to 12) 21 (15 to 28) ..
12 weeks 22 (20) 24 (22) 29 (21) 2 (–6 to 10) 7 (–1 to 14) –5 (–12 to 3) ..
26 weeks 33 (21) 22 (24) 36 (20) –11 (–19 to –3) 2 (–5 to 10) –14 (–21 to –6) ..
52 weeks 35 (21) 27 (23) 40 (22) –8 (–16 to 1) 5 (–3 to 13) –13 (–20 to –5) <0·0001
Pain–free grip strength
3 weeks 4 (18) 38 (27) 8 (19) 34 (26 to 42) 4 (–4 to 12) 30 (23 to 38) ..
6 weeks 14 (21) 45 (26) 18 (24) 31 (22 to 39) 4 (–5 to 12) 27 (18 to 35) ..
12 weeks 30 (30) 24 (25) 35 (33) –6 (–17 to 5) 5 (–5 to 16) –11(–21 to –0·3) ..
26 weeks 42 (28) 31 (31) 48 (29) –11(–22 to –0·4) 6 (–5 to 16) –17 (–28 to –6) ..
52 weeks 51 (24) 37 (40) 61 (26) –14 (–25 to –3) 10 (–1 to 21) –24 (–35 to –13) <0·001
Secondary outcome measures
Maximum grip strength
3 weeks –0·3 (12) 21 (23) –1 (20) 21 (14 to 28) –1 (–7 to 6) 22 (15 to 29) ..
6 weeks 3 (18) 24 (26) 9 (23) 21 (13 to 29) 5 (–3 to 13) 15 (7 to 23) ..
12 weeks 10 (24) 14 (27) 17 (26) 4 (–5 to 14) 7 (–2 to 16) –3 (–12 to 7) ..
26 weeks 18 (25) 17 (28) 23 (25) –1 (–11 to 8) 4 (–5 to 14) –6 (–15 to 4) ..
52 weeks 22 (24) 22 (36) 27 (29) 0 (–11 to 11) 5 (–6 to 16) –5 (–15 to 6) <0·0001
Pressure pain threshold
3 weeks 3 (20) 24 (23) 4 (22) 21 (13 to 29) 1 (–7 to 9) 20 (12 to 28) ..
6 weeks 7 (25) 35 (41) 16 (24) 28 (16 to 39) 9 (–2 to 20) 19 (8 to 30) ..
12 weeks 18 (31) 16 (27) 19 (25) –1 (–11 to 9) 2 (–8 to 12) –3 (–13 to 7) ..
26 weeks 27 (26) 16 (29) 35 (27) –11 (–21 to –1) 8 (–2 to 18) –19 (–29 to –10) ..
52 weeks 40 (36) 27 (33) 38 (30) –13 (–25 to –1) –2 (–14 to 10) –11 (–23 to 0·3) <0·0001
Patient satisfaction
6 weeks 67 (25) 90 (16) 82 (14) 23 (15 to 31) 15 (7 to 23) 8 (0·2 to 16) ..
12 weeks 74 (20) 81 (23) 83 (16) 6 (–1 to 14) 9 (2 to 16) –2 (–9 to 5) ..
26 weeks 76 (24) 78 (23) 84 (20) 2 (–6 to 10) 8 (0·2 to 16) –6 (–14 to 2) ..
52 weeks 78 (25) 77 (23) 86 (18) –1 (–9 to 7) 8 (–1 to 16) –9 (–16 to –1) ..
Data are mean (SD) unless otherwise indicated. *Differences in trend over time between intervention groups.
Table 3: Improvement in primary and secondary outcome measures
For personal use.  Only reproduce with permission from The Lancet Publishing Group.
as those of the intention-to-treat analysis. The success rates
at 6 weeks were 92% (55) for injections, 48% (21) for
physiotherapy, and 33% (19) for the wait-and-see policy.
Although 87 (47%) patients reported adverse reactions,
most were mild (table 4). Increased pain after treatment,
and radiating pain were reported more frequently for
physiotherapy and injections than for the wait-and-see
policy. The frequency of other presumed adverse effects,
such as facial flushes or skin irritations, was low, and similar
for injections and physiotherapy. For six patients allocated
to physiotherapy, the intensity of therapy was adjusted
because of adverse reactions. 
At 6 weeks, the research physiotherapists correctly
guessed the allocated treatment in 94 of 181 patients.
Correct guesses were made for 29 patients (50%) in the
injection group, 24 (38%) in the physiotherapy group, and
41 (72%) in the wait-and-see group. A slip of the tongue by
the patient disclosed allocation in 17 instances. In 41 of 181
instances, the guess was based on the course of symptoms
during the intervention period, and was correct for 26
patients. In 115 patients, the physiotherapists just took a
guess, which turned out to be correct in 45 instances. 
Discussion
Our results suggest that corticosteroid injections are the best
treatment option in the short-term for patients with lateral
epicondylitis. The differences compared with physiotherapy
and a wait-and-see policy were large, clinically relevant, and
consistent for all outcome measures. However, these
beneficial effects only persisted for a short time. At long-
term follow-up, our findings suggest that physiotherapy
becomes the best option, followed by a wait-and-see policy. 
The poor results of corticosteroid injections after 
12 weeks might seem surprising. However, results of two
other trials28,29 also indicated poor long-term outcomes for
corticosteroid injections compared with alternative
conservative treatments for epicondylitis, although the
differences were not as large or consistent as those seen in
our trial. We believe that the poor long-term outcome of
corticosteroids is associated with a high frequency 
of additional treatment after 6 weeks. The high number of
relapses and recurrences (23, 37%) could be explained in a
couple of ways. First, corticosteroid injections might be
harmful to the tendon, although reported adverse reactions
were generally mild. Second, patients might not have
followed the advice given by their family doctor, and might
have overtaxed their elbow after receiving an injection. 
Our trial was done in a primary-care setting. Selection
bias was prevented by use of a strictly organised selection
and randomisation procedure. Furthermore, drop-out rate
was kept to a minimum (<2%, 2). However, in a pragmatic
trial, comparing different types of interventions,
implementation of a blinded and unbiased assessment of
outcome is difficult. The research physiotherapists were
aware of the treatment being received by patients in some
instances, and the frequency of disclosure was not wholly
consistent across interventions. However, the clues for
guessing the assigned treatment were often the results of
examination (course of symptoms), which could indicate
that the assessment of outcome measures itself (as part of
the examination) was not greatly affected.30 Furthermore,
before randomisation, patients were asked about their
preferences with respect to treatment, because this could
have affected their assessment of treatment efficacy. A large
number of patients indicated a preference for
physiotherapy, but these preferences showed little effect on
outcome.
The pragmatic design of our study enhances the
possibilities for generalisation of its findings to everyday
ARTICLES
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precipitating cause. Differences in these prognostic variables
had little effect on outcome of analyses. We therefore
present the unadjusted analysis.
In the group treated with a wait-and-see policy, 
20 patients (34%) took pain medication during the
intervention period (seven paracetamol and 15 NSAIDs).
17 patients (27%) in the injection group received two
injections, nine (15%) received three injections. The
median amount of liquid injected increased from 0·9 mL
(IQR 0·5–1·4) for the first dose to 1·5 mL (1·0–1·5) for the
third. Ten patients (16%) took pain medication (six
paracetamol and five NSAIDs). Physiotherapy consisted of
eight sessions of about 30 min in most patients. Ten
patients (16%) took pain medication (seven paracetamol
and seven NSAIDs). NSAIDs were generally prescribed by
the family doctor. 
Only 14 (24%) patients in the wait-and-see group
received additional treatment for elbow complaints during
the 1-year follow-up, compared with 39 (63%) in the
injection group and 52 (81%) in the physiotherapy group
(table 2). Many patients allocated to physiotherapy
continued their treatment after the intervention period, but
this lasted for less than 6 weeks in most cases.
Figure 2 shows the success rates at all assessments. At 
6 weeks, success was reported by 57 (92%) patients in the
injection group, 30 (47%) in the physiotherapy group, and
19 (32%) in the wait-and-see group. However, the
beneficial effects of corticosteroid injections were only seen
at short-term follow-up. At 52 weeks, success rates were
69% (43) for injections, 91% (58) for physiotherapy, and
83% (49) for the wait-and-see policy. 
At 6 weeks, significant differences in favour of
corticosteroid injections were seen for all primary and
secondary outcomes. By contrast, at 26 and 52 weeks,
significant differences for nearly all outcome measures were
noted in favour of physiotherapy compared with injections
(table 3). Physiotherapy also showed better results
compared with the wait-and-see policy, but these
differences were small (between 5% and 10%), and not
significant. The long-term outcome of the wait-and-see
policy was also better than injections, but most differences
were small (<12%) and not significant for most outcome
measures.
MANOVA for repeated measures showed that the course
of symptoms was very different across intervention groups
for all outcome measures (p<0·0001). The course of the
severity of pain, elbow disability, severity of symptoms, grip
strength, and pressure pain threshold concur with the
results reported for success rate. 
We did an alternative analysis in which we excluded 
21 patients who were not treated according to protocol
(figure 1) and three patients who were incorrectly enrolled.
The results of the alternative analysis were much the same
Wait-and-see Corticosteroid Physiotherapy
policy (n=59) injection (n=62) (n=64)
Number of patients 10 (17%) 36 (58%) 41 (64%)
reporting adverse effects
Increased pain 1 day 1 (2%) 6 (10%) 9 (14%)
Increased pain >1 day 1 (2%) 10 (16%) 11 (17%)
Radiating pain to forearm 7 (12%) 17 (27%) 27 (42%)
or upper arm
Facial flush 0 2 (3%) 0
Skin irritation 0 3 (5%) 3 (5%)
Red swollen elbow 0 2 (3%) 3 (5%)
Change of skin colour 0 7 (11%) 3 (5%)
Other minor or temporary 1 (2%) 8 (13%) 17 (27%)
adverse reactions
Data are number of patients (%).
Table 4: Adverse reactions during 6-week intervention period 
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care. However, not all eligible patients with epicondylitis
were referred to a research centre and enrolled in the trial.
When asked about the reasons for not referring patients,
family doctors indicated that exclusion criteria were
important, but that busy office hours or forgetfulness were
the main reasons for missed cases. We therefore feel that the
external validity of our findings was not substantially
threatened by inadequate patient referral. Furthermore,
although consistent with Dutch national guidelines for
epicondylitis, the maximum number of injections (three) in
our trial might be somewhat higher than usual in primary
care. Finally, we excluded patients with a symptom
duration less than 6 weeks, since we felt that corticosteroid
injections or physiotherapy might not be indicated in these
individuals.
In view of our results, we have no reason to believe that
awaiting spontaneous recovery will not be adequate
treatment for patients with a short duration of symptoms at
presentation. Patients should be properly informed about
the advantages and disadvantages of the treatment options
for lateral epicondylitis. If individuals prefer quick relief of
symptoms, a corticosteroid injection might be suitable, but
the long-term outcome can be poor. A wait-and-see policy,
with adequate advice and pain medication if needed, will
often suffice. The highest probability of recovery after 
6 months, however, was associated with physiotherapy, but
differences compared with the wait-and-see policy were
small. Whether or not the surplus value of physiotherapy is
worth the additional resources needed for treatment is
debatable.
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